53. シェーグレン症候群 Sjogren syndrome Clinical trials / Disease details
臨床試験数 : 305 / 薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2014-004523-51-GR (EUCTR) | 14/02/2017 | 03/01/2017 | UCB Proof of Concept Study in patients with Primary Sjogren’s Syndrome | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UCB5857 OVER 12 WEEKS IN SUBJECTS WITH PRIMARY SJOGREN’S SYNDROME | Primary Sjogren’s Syndrome MedDRA version: 19.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: UCB5857 Product Code: UCB5857 INN or Proposed INN: UCB5857 Other descriptive name: UCB5857 Product Name: UCB5857 Product Code: UCB5857 INN or Proposed INN: UCB5857 Other descriptive name: UCB5857 Product Name: UCB5857 Product Code: UCB5857 INN or Proposed INN: UCB5857 Other descriptive name: UCB5857 | UCB Celltech, UK | NULL | Not Recruiting | Female: yes Male: yes | 58 | Phase 2 | France;Greece;Spain;Italy;United Kingdom;Sweden | ||
| 2 | EUCTR2014-004523-51-SE (EUCTR) | 24/08/2016 | 05/07/2016 | UCB Proof of Concept Study in patients with Primary Sjogren’s Syndrome | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UCB5857 OVER 12 WEEKS IN SUBJECTS WITH PRIMARY SJOGREN’S SYNDROME | Primary Sjogren’s Syndrome MedDRA version: 19.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: UCB5857 Product Code: UCB5857 INN or Proposed INN: UCB5857 Other descriptive name: UCB5857 Product Name: UCB5857 Product Code: UCB5857 INN or Proposed INN: UCB5857 Other descriptive name: UCB5857 Product Name: UCB5857 Product Code: UCB5857 INN or Proposed INN: UCB5857 Other descriptive name: UCB5857 | UCB Celltech, UK | NULL | Not Recruiting | Female: yes Male: yes | 58 | Phase 2 | France;Greece;Spain;Netherlands;Italy;United Kingdom;Sweden | ||
| 3 | NCT02610543 (ClinicalTrials.gov) | October 2015 | 18/11/2015 | UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome | A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy of UCB5857 Over 12 Weeks in Subjects With Primary Sjögren's Syndrome | Primary Sjögren's Syndrome | Drug: UCB5857;Drug: Placebo | UCB Celltech | PRA Health Sciences | Terminated | 18 Years | 75 Years | All | 27 | Phase 2 | France;Italy;Spain;Sweden;United Kingdom;Greece |
| 4 | EUCTR2014-004523-51-ES (EUCTR) | 14/09/2015 | 01/06/2015 | UCB Proof of Concept Study in patients with Primary Sjogren?s Syndrome | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UCB5857 OVER 12 WEEKS IN SUBJECTS WITH PRIMARY SJOGREN?S SYNDROME | Primary Sjogren?s Syndrome MedDRA version: 18.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: UCB5857 Product Code: UCB5857 INN or Proposed INN: UCB5857 Other descriptive name: UCB5857 Product Name: UCB5857 Product Code: UCB5857 INN or Proposed INN: UCB5857 Other descriptive name: UCB5857 Product Name: UCB5857 Product Code: UCB5857 INN or Proposed INN: UCB5857 Other descriptive name: UCB5857 | UCB Celltech, UK | NULL | Not Recruiting | Female: yes Male: yes | 58 | Phase 2 | France;Greece;Spain;Netherlands;Italy;United Kingdom;Sweden | ||
| 5 | EUCTR2014-004523-51-IT (EUCTR) | 25/08/2015 | 15/12/2017 | UCB PROOF OF CONCEPT STUDY IN PATIENTS WITH PRIMARY SJ?GREN'S SYNDROME | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OFCONCEPTSTUDY TO EVALUATE THE EFFICACY AND SAFETY OF UCB5857 OVER 12 WEEKS IN SUBJECTS WITH PRIMARY SJ?GREN'S SYNDROME - NA | Primary Sj?gren's Syndrome MedDRA version: 20.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: UCB5857 Product Code: UCB5857 INN or Proposed INN: UCB5857 Other descriptive name: UCB5857 Product Name: UCB5857 Product Code: UCB5857 INN or Proposed INN: UCB5857 Other descriptive name: UCB5857 Product Name: UCB5857 Product Code: UCB5857 INN or Proposed INN: UCB5857 Other descriptive name: UCB5857 | UCB CELLTECH (UK BRANCH OF UCB PHARMA SA) | NULL | Not Recruiting | Female: yes Male: yes | 58 | Phase 2 | France;Greece;Spain;Netherlands;United Kingdom;Italy;Sweden | ||
| 6 | EUCTR2014-004523-51-FR (EUCTR) | 28/05/2015 | 20/07/2015 | UCB Proof of Concept Study in patients with Primary Sjogren’s Syndrome | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UCB5857 OVER 12 WEEKS IN SUBJECTS WITH PRIMARY SJOGREN’S SYNDROME | Primary Sjogren’s Syndrome MedDRA version: 18.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: UCB5857 Product Code: UCB5857 INN or Proposed INN: UCB5857 Other descriptive name: UCB5857 Product Name: UCB5857 Product Code: UCB5857 INN or Proposed INN: UCB5857 Other descriptive name: UCB5857 Product Name: UCB5857 Product Code: UCB5857 INN or Proposed INN: UCB5857 Other descriptive name: UCB5857 | UCB Celltech, UK | NULL | Not Recruiting | Female: yes Male: yes | 58 | Phase 2 | France;Greece;Spain;Netherlands;Italy;United Kingdom;Sweden | ||
| 7 | EUCTR2014-004523-51-GB (EUCTR) | 18/05/2015 | 01/04/2015 | UCB Proof of Concept Study in patients with Primary Sjogren’s Syndrome | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UCB5857 OVER 12 WEEKS IN SUBJECTS WITH PRIMARY SJOGREN’S SYNDROME | Primary Sjogren’s Syndrome MedDRA version: 19.1;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: UCB5857 Product Code: UCB5857 INN or Proposed INN: UCB5857 Other descriptive name: UCB5857 Product Name: UCB5857 Product Code: UCB5857 INN or Proposed INN: UCB5857 Other descriptive name: UCB5857 Product Name: UCB5857 Product Code: UCB5857 INN or Proposed INN: UCB5857 Other descriptive name: UCB5857 | UCB Celltech, UK | NULL | Not Recruiting | Female: yes Male: yes | 58 | Phase 2 | France;Greece;Spain;Italy;United Kingdom;Sweden |